James Chih‐Hsin Yang

109.5k total citations · 43 hit papers
698 papers, 66.2k citations indexed

About

James Chih‐Hsin Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, James Chih‐Hsin Yang has authored 698 papers receiving a total of 66.2k indexed citations (citations by other indexed papers that have themselves been cited), including 516 papers in Pulmonary and Respiratory Medicine, 516 papers in Oncology and 136 papers in Molecular Biology. Recurrent topics in James Chih‐Hsin Yang's work include Lung Cancer Treatments and Mutations (480 papers), Lung Cancer Research Studies (204 papers) and Colorectal Cancer Treatments and Studies (175 papers). James Chih‐Hsin Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (480 papers), Lung Cancer Research Studies (204 papers) and Colorectal Cancer Treatments and Studies (175 papers). James Chih‐Hsin Yang collaborates with scholars based in Taiwan, United States and South Korea. James Chih‐Hsin Yang's co-authors include Steven A. Rosenberg, Richard M. Sherry, Suzanne L. Topalian, Donald E. White, Tony Mok, Douglas J. Schwartzentruber, Seth M. Steinberg, Nicholas P. Restifo, Udai S. Kammula and Claudia A. Seipp and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

James Chih‐Hsin Yang

679 papers receiving 65.0k citations

Hit Papers

Gefitinib or Carboplatin–... 1988 2026 2000 2013 2009 2013 2002 2003 2006 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
    2009 6.4k citations Tony Mok, Yi‐Long Wu et al. profile →
  2. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
    2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  3. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
    2002 2.2k citations Mark E. Dudley, John R. Wunderlich et al. profile →
  4. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
    2003 2.1k citations James Chih‐Hsin Yang, Leah Haworth et al. profile →
  5. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
    2006 2.0k citations Mark E. Dudley, John R. Wunderlich et al. profile →
  6. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
    1988 1.8k citations Steven A. Rosenberg, Paul Aebersold et al. profile →
  7. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
    2011 1.6k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. Clinical Cancer Research profile →
  8. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
    2015 1.6k citations Pasi A. Jänne, James Chih‐Hsin Yang et al. profile →
  9. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
    1998 1.5k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. profile →
  10. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
  11. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
    2011 1.2k citations Yi‐Long Wu, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  12. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
    2016 1.1k citations James Chih‐Hsin Yang, Lecia V. Sequist et al. profile →
  13. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
    2008 1.0k citations Mark E. Dudley, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  14. Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
    1989 786 citations Steven A. Rosenberg, Michael T. Lotze et al. Annals of Surgery profile →
  15. Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2
    1994 779 citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. profile →
  16. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
    2012 776 citations Vera Hirsh, Keunchil Park et al. profile →
  17. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
    2014 772 citations Paul F. Robbins, Yong F. Li et al. profile →
  18. Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
    2005 771 citations Giao Q. Phan, Martha Quezado et al. Journal of Clinical Oncology profile →
  19. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    2015 715 citations James Chih‐Hsin Yang, Lecia V. Sequist et al. profile →
  20. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
    2006 646 citations Joseph Blansfield, Khoi Q. Tran et al. Journal of Clinical Oncology profile →
  21. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
    2016 641 citations Kenneth S. Thress, Mireille Cantarini et al. Journal of Clinical Oncology profile →
  22. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
    2016 597 citations Paul F. Robbins, Jessica S. Crystal et al. profile →
  23. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
    2014 585 citations Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research profile →
  24. Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
    2016 582 citations Tony Mok, James Chih‐Hsin Yang et al. profile →
  25. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
    2003 573 citations James Chih‐Hsin Yang, Richard M. Sherry et al. Journal of Clinical Oncology profile →
  26. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
    2007 537 citations James Chih‐Hsin Yang, Marybeth S. Hughes et al. profile →
  27. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
    2016 523 citations Peter Ballard, James Yates et al. Clinical Cancer Research profile →
  28. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
    2007 519 citations Jacob A. Klapper, Franz O. Smith et al. Clinical Cancer Research profile →
  29. Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
    2015 506 citations Sanja Stevanović, Lindsey M. Draper et al. Journal of Clinical Oncology profile →
  30. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    2020 491 citations James Chih‐Hsin Yang, Terufumi Kato et al. Journal of Clinical Oncology profile →
  31. Toxicities of Immunotherapy for the Practitioner
    2015 465 citations James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  32. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
    2015 430 citations James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  33. Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
    2012 429 citations Kang‐Yi Su, Hsuan‐Yu Chen et al. Journal of Clinical Oncology profile →
  34. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
    2017 405 citations Tony Mok, James Chih‐Hsin Yang et al. profile →
  35. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    2017 398 citations Luis Paz‐Ares, Kenneth J. O’Byrne et al. profile →
  36. Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
    2013 383 citations Vera Hirsh, Chun‐Ming Tsai et al. profile →
  37. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    2017 380 citations James Chih‐Hsin Yang, Dong‐Wan Kim et al. Journal of Clinical Oncology profile →
  38. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
    2020 295 citations Lecia V. Sequist, Helena A. Yu et al. profile →
  39. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
    2018 225 citations Yi‐Long Wu, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  40. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    2021 196 citations James Chih‐Hsin Yang, Pasi A. Jänne et al. profile →
  41. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    2022 95 citations Lecia V. Sequist, Helena A. Yu et al. profile →
  42. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    2023 95 citations Tony Mok, Yi‐Long Wu et al. profile →
  43. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
    2023 89 citations James Chih‐Hsin Yang, Luis Paz‐Ares et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Chih‐Hsin Yang Taiwan 107 46.1k 33.9k 18.4k 18.0k 9.4k 698 66.2k
Jedd D. Wolchok United States 119 45.3k 1.0× 11.0k 0.3× 16.2k 0.9× 29.7k 1.7× 4.6k 0.5× 568 65.0k
Hope S. Rugo United States 90 31.3k 0.7× 16.6k 0.5× 11.2k 0.6× 6.2k 0.3× 11.5k 1.2× 847 45.2k
Kenneth J. Pienta United States 116 18.0k 0.4× 17.5k 0.5× 21.8k 1.2× 7.2k 0.4× 12.1k 1.3× 675 49.8k
Michael B. Atkins United States 91 25.3k 0.5× 12.6k 0.4× 16.0k 0.9× 12.0k 0.7× 6.3k 0.7× 577 40.7k
Antoni Ribas United States 110 39.7k 0.9× 7.5k 0.2× 27.4k 1.5× 22.6k 1.3× 6.3k 0.7× 551 61.0k
Roy S. Herbst United States 102 31.9k 0.7× 26.5k 0.8× 17.0k 0.9× 5.5k 0.3× 9.2k 1.0× 583 50.9k
Razelle Kurzrock United States 119 24.9k 0.5× 12.3k 0.4× 21.0k 1.1× 8.2k 0.5× 13.3k 1.4× 1.2k 60.4k
Fabrice André France 95 20.5k 0.4× 13.0k 0.4× 13.9k 0.8× 4.8k 0.3× 14.1k 1.5× 675 38.0k
David L. Rimm United States 102 19.9k 0.4× 7.9k 0.2× 17.9k 1.0× 7.0k 0.4× 8.2k 0.9× 547 41.4k
Johann S. de Bono United Kingdom 108 22.3k 0.5× 29.0k 0.9× 18.9k 1.0× 3.6k 0.2× 14.1k 1.5× 1.0k 53.2k

Countries citing papers authored by James Chih‐Hsin Yang

Since Specialization
Citations

This map shows the geographic impact of James Chih‐Hsin Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Chih‐Hsin Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Chih‐Hsin Yang more than expected).

Fields of papers citing papers by James Chih‐Hsin Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Chih‐Hsin Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Chih‐Hsin Yang. The network helps show where James Chih‐Hsin Yang may publish in the future.

Co-authorship network of co-authors of James Chih‐Hsin Yang

This figure shows the co-authorship network connecting the top 25 collaborators of James Chih‐Hsin Yang. A scholar is included among the top collaborators of James Chih‐Hsin Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Chih‐Hsin Yang. James Chih‐Hsin Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hsu, Chia‐Chi, et al.. (2025). Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumors. Journal of the Formosan Medical Association. 125(4). 398–405.
2.
Liao, Wei‐Yu, Chao‐Chi Ho, Jin‐Yuan Shih, et al.. (2024). Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure. Journal of the Formosan Medical Association. 124(8). 759–766. 1 indexed citations
3.
4.
Seitter, Samantha J., Richard M. Sherry, James Chih‐Hsin Yang, et al.. (2021). Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. Clinical Cancer Research. 27(19). 5289–5298. 72 indexed citations
5.
Yu, Helena A., Luis Paz‐Ares, James Chih‐Hsin Yang, et al.. (2020). Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer. Clinical Cancer Research. 27(4). 992–1002. 31 indexed citations
6.
Melosky, B., et al.. (2017). Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC. Cancer Treatment and Research Communications. 11. 10–16.
7.
Schüler, Martin, Yi‐Long Wu, Vera Hirsh, et al.. (2016). First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. QUT ePrints (Queensland University of Technology). 1 indexed citations
8.
Lin, Yen‐Ting, Chong‐Jen Yu, James Chih‐Hsin Yang, & Jin‐Yuan Shih. (2016). Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review. Clinical Lung Cancer. 17(5). e77–e94. 31 indexed citations
9.
Ballard, Peter, James Yates, Zhenfan Yang, et al.. (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical Cancer Research. 22(20). 5130–5140. 523 indexed citations breakdown →
10.
Stevanović, Sanja, Lindsey M. Draper, Michelle M. Langhan, et al.. (2015). Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology. 33(14). 1543–1550. 506 indexed citations breakdown →
11.
Robbins, Paul F., Sadik H. Kassim, Thai L.N. Tran, et al.. (2014). A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research. 21(5). 1019–1027. 585 indexed citations breakdown →
12.
Sequist, Lecia V., James Chih‐Hsin Yang, Nobuyuki Yamamoto, et al.. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27). 3327–3334. 2461 indexed citations breakdown →
13.
Su, Kang‐Yi, Hsuan‐Yu Chen, Ker-Chau Li, et al.. (2012). Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(4). 433–440. 429 indexed citations breakdown →
14.
Chung, Kuei‐Pin, Shang‐Gin Wu, Jenn‐Yu Wu, et al.. (2012). Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR. Clinical Cancer Research. 18(12). 3470–3477. 54 indexed citations
15.
Wu, Jenn‐Yu, Chong‐Jen Yu, Yeun‐Chung Chang, et al.. (2011). Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer. Clinical Cancer Research. 17(11). 3812–3821. 361 indexed citations
16.
Dudley, Mark E., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2008). Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology. 26(32). 5233–5239. 1017 indexed citations breakdown →
17.
Blansfield, Joseph, Khoi Q. Tran, Andrew L. Feldman, et al.. (2006). Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. Journal of Clinical Oncology. 24(15). 2283–2289. 646 indexed citations breakdown →
18.
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377. 1234 indexed citations breakdown →
19.
Yang, James Chih‐Hsin, Min‐Liang Kuo, JC Chen, & Yee‐Chun Chen. (1999). Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. British Journal of Cancer. 81(5). 796–799. 115 indexed citations
20.
Rosenberg, Steven A., Michael T. Lotze, James Chih‐Hsin Yang, et al.. (1989). Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients. Annals of Surgery. 210(4). 474–485. 786 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by Hope S. Rugo Breakdown of academic impact, for papers by Kenneth J. Pienta Breakdown of academic impact, for papers by Michael B. Atkins Breakdown of academic impact, for papers by Antoni Ribas Breakdown of academic impact, for papers by Roy S. Herbst Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Fabrice André Breakdown of academic impact, for papers by David L. Rimm Breakdown of academic impact, for papers by Johann S. de Bono
Rankless by CCL
2026